Meet Evernorth Signature Pharmacy Benefit Services
A simpler, more patient-focused way to make pharmacy benefits more predictable.
Pharmacy benefits built for what’s next.
Drug costs are rising, especially for high‑cost brand medications. Employers need a clearer view of what they’re paying, and patients want fewer surprises. Evernorth Signature℠ Pharmacy Benefit Services gives you more predictable costs and the flexibility to build a benefit solution around your business—while ensuring patients always get the lowest available cost at the pharmacy counter.
Why PBMs still matter
PBMs help keep drug costs down by creating competition, negotiating prices and supporting medication safety. But there’s still room to make the system work better.
Percentage who feel confident in AI accuracy in health care
10%
of prescriptions
drive over 80% of total drug spend1
~18,000%
increase
in the median launch price of new drugs since 20082
90%
of prescriptions
are generics but they only account for ~12% of drug spend3
The real value of PBMs
Pharmacy benefits support more than 289 million Americans and help prevent about 100 million medication errors every year.
Key insights
Affordability
Negotiated costs and formulary management
Scale-based purchasing power
Safety and clinical coordination
Prescription drug interaction checks
Dose and allergy safeguards
Adherence and outcomes
Reduced hospitalizations
Fewer ER visits
Increased medication adherence
Why the pressure is growing
Here’s the challenge: People are living longer and managing more chronic conditions, so the need for affordable care keeps growing. At the same time, rising costs and supply pressures make that affordability harder to deliver. Employers need pharmacy benefits that make costs clearer, more predictable and easier to manage.
New drugs are reaching the market faster—but they often come with eye-opening price tags.
And patients increasingly expect health care to be as simple and transparent as any other shopping experience.
1 in 5
Americans will be 65+ by 20304
6 in 10
adults live with at least one chronic condition5
90%
of $4.9T in health spend is tied to chronic conditions6
When competition works—and when it doesn’t
Competition is one of the best ways to keep drug costs in check. But a small number of expensive brand-name and specialty drugs account for a big share of spending. That’s where PBMs come in. By negotiating prices, managing formularies and using other tools, PBMs help balance drug manufacturers’ pricing power. The result: PBMs can save clients and consumers 40% to 50% a year on prescription drug and related medical costs compared with not having a pharmacy benefit.
The system works best when there’s real competition.
$467B
annual savings
by switching to biosimilars and generics7
~2%
of prescriptions
continues to drive nearly half of overall drug spending8
Evernorth Signature Pharmacy Benefit Services puts patients first
Patients want to pay less at the pharmacy counter. Employers want lower, more predictable costs and a clearer view of their benefits. Our model brings it all together by applying competition, simplicity and clinical expertise right where it matters—the pharmacy counter.
Savings upfront: Patients get the lowest available cost when they fill any medication.
Less complexity: One clear benefit and pricing experience for employers and patients.
Confidence with every fill: The same rigorous safety checks and coordinated care every time.
Introducing Evernorth Signature Pharmacy Benefit Services
Our patient-centric model offers a simpler, more transparent and more predictable approach to managing prescription drug expenses for patients and employers.
The U.S. Generic & Biosimilar Medicines Savings Report (2025) – AAM, using IQVIA data. AAM-2025-Generic-Biosimilar-Medicines-Savings-Report-WEB.pdf
Agboola F, Lin GA, Lee W, Wright A, Phillips M, Lee M, Koola Fisher C, Emond SK. Launch Price and Access Report. Institute for Clinical and Economic Review, October 23, 2025. https://icer.org/assessment/launch-price-and-access-2025/#overview
Mulcahy AW, Schwam D, Lovejoy SL; RAND. International Prescription Drug Price Comparisons: Estimates Using 2022 Data: Contractor Project Report. 2024 Feb. In: Comparing Prescription Drugs in the U.S. and Other Countries: Prices and Availability [Internet]. Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); 2024 Jan 31. Available from: https://www.ncbi.nlm.nih.gov/books/NBK611303/
“Chronic Diseases in America.” Cdc.gov, 30 Oct. 2018, stacks.cdc.gov/view/cdc/61396.
US Census Bureau
National Center for Chronic Disease Prevention and Health Promotion https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html
Parasrampuria, S. and Murphy, S. Trends in Prescription Drug Spending, 2016-2021. Washington, DC: Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. September 2022
“2025 U.S. Generic & Biosimilar Medicines Savings Report.” Association for Accessible Medicines, 2 Apr. 2026, accessiblemeds.org/resources/reports/2025-savings-report/?ref=chaindrugreview.com. Accessed 6 May 2026.